Mucocutaneous Symptoms of Multisystem Inflammatory Syndrome in Pediatric Patients
The mucocutaneous features seen in hospitalized children with MIS-C and how these findings are associated with the onset of systemic symptoms are characterized.
The mucocutaneous features seen in hospitalized children with MIS-C and how these findings are associated with the onset of systemic symptoms are characterized.
The cutaneous signs thus reported as COVID-19 related, their incidence, clinic-pathologic features, and diagnostic and prognostic values are described.
Study authors compared the effect of aqueous olanexidine and aqueous povidone-iodine on the incidence of surgical site infection following clean-contaminated surgery.
A literature review assessed English-language studies and case reports that focused on urticaria in patients with COVID-19.
The COVID-19 pandemic has illuminated an ongoing concern about antimicrobial resistance in dermatology and requires a recommitment from clinicians to follow guidelines that promote good stewardship.
Men with severe hair loss were significantly more likely to test positive for COVID-19, finds study data.
A first clinical experience with brodalumab in an HIV-positive patient proves successful and may imply the utility of brodalumab in this patient group.
According to Mylan, the administration of the recalled product may lead to “serious adverse events including, but not limited to, local irritation, vasculitis/phlebitis, antigenic or allergic reactions, and microvascular obstruction, including pulmonary embolism.”
SB206 12% represents a well-tolerated topical treatment for molluscum contagiosum that can be applied at home by patients or caregivers, solving an unmet medical need.
The association of S aureus with food sensitization and allergy could influence interventions aimed at inducing and maintaining tolerance to food allergens in eczematous infants.